Societal views on patents

societal views patents
legal scholars
economists
activists
policymakers
industries
trade organizations held differing views patents engaged contentious debates subject
critical perspectives emerged nineteenth century
recent debates discussed merits faults software patents biological patents
debates part larger discourse intellectual property protection reflects differing perspectives copyright
criticism patents reached early peak victorian britain
campaign patenting expanded target copyright
judgment historian adrian johns
remains day strongest campaign undertaken intellectual property
coming close abolishing patents
prominent activists isambard kingdom brunel
william robert grove
william armstrong robert
macfie inventors entrepreneurs
supported radical laissez faire economists
economist published anti patent views
law scholars
scientists
concerned patents obstructing research
manufacturers
johns summarizes main arguments
similar debates place time european countries france
prussia
switzerland netherlands
usa
based criticism patents state granted monopolies inconsistent free trade
netherlands abolished patents
established
reintroduce
switzerland
criticism patents delayed introduction patent laws
theoretical problem patent rights discussed law professors michael heller rebecca sue eisenberg
based heller theory tragedy anticommons
authors
disputing role patents general motivating invention disclosure
argue biomedical research key areas intellectual property rights fragmented
effectively
advantage require agreement owners fragments
hand
authors problem predict
persistent transitional
case
holders intellectual property rights find ways address problem arises
patent pools
recently growing concern economists scientists patents shown retard technical progress innovation
fields biotechnology nanotechnology disproportionally hampered
ars technica reports
patents mention single walled carbon nanotubes
intel covers diameter
rice university holds material percent pure nanotube
nightmare faced attempting innovate space obvious
full discussion criticisms intellectual monopoly
long standing argument patents hinder innovation give rise
troll
entities
holding company
pejoratively
patent troll
owns portfolio patents
sues infringement patents develop technology
world trade organization
wto
reached agreement
developing country options obtaining needed medications compulsory licensing importation cheaper versions drugs
patent expiration
recently issue received additional coverage hiv aids drugs
governments companies brazil
india
thailand uganda started challenge pharmaceutical patents
arguing human lives important patents
copyright
international trade laws
economic interest pharmaceutical industry
anti retroviral therapy long unaffordable people suffering hiv
aids developing countries
proponents generic antiviral drugs argue human justifies breach patent law
thai government pharmaceutical organization started producing generic antiviral drugs march cost monthly treatment person plummeted
making treatment affordable
response government thailand list
copyright violators
fact production antiviral drugs subject copyright
united states
government brazil declared merck efavirenz anti retroviral drug
public interest
medicine
challenged merck negotiate lower prices government brazil strip patent issuing compulsory license
reported ghana
tanzania
democratic republic congo ethiopia similar plans produce generic antiviral drugs
western pharmaceutical companies initially responded legal challenges
promised introduce alternative pricing structures developing countries ngos
july nobel prize winning scientist sir john sulston called international biomedical treaty clear issues patents
response criticisms pharmaceutical patents pointed medicines essential drugs list subject patent monopoly countries monopolies impeding health care aware medicines question
hiv
aids related drugs
patented country
response
patents forms research funding
medicines question developed decades
citation needed
quoting world health organisation report
trevor jones
director research development wellcome foundation
argued patent monopolies create monopoly pricing
argued companies monopolies
set prices largely willingness
ability pay
taking account country
disease regulation
receiving competition legalized generics
